Skip to content
DataLookout
Start free
Menu

NCT07906717

A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Recruitment opened
    • Trial sites expanded: 0 → 4 locations
    • Start date changed from estimate of Nov 6, 2026 to Oct 29, 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Overall Survival (OS)
Timeframe: Up to 21 months

Secondary (8)

Radiographic Progression-Free Survival (rPFS)
Progression-Free Survival (PFS)
Time to Symptomatic Progression (TSP)
Time to Skeletal-Related Events (TSRE)
Time to Pain Progression (TTPP)
Show 3 moreShow less
Number of Participants with Treatment-Emergent Adverse Event (TEAE) by Severity
Number of Participants with Abnormalities in Clinical Laboratory Tests
Plasma Concentration of JNJ-101556143

Arms and interventions

JNJ-101556143 + Best Supportive CareExperimental

Participants will receive JNJ-101556143 orally once daily along with Best Supportive Care. Treatment will continue until discontinuation criteria are met.

Placebo + Best Supportive CarePlacebo comparator

Participants will receive matching placebo orally once daily along with Best Supportive Care. Treatment will continue until discontinuation criteria are met.

Drugs: JNJ-101556143, Placebo, Best Supportive Care

Sites

4 sites in 2 countries

United States 3, Israel 1